COVID-19: CDC, FDA and CMS Guidance

This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.

The Centers for Medicare & Medicaid Services has released a Medicare payment code effective Feb. 24 for administering the combination monoclonal antibody therapy Evusheld to prevent COVID-19 in certain patients.
The Centers for Disease Control and Prevention yesterday said more than 90% of the U.S. population now lives in a county with a low or medium COVID-19 Community Level, a new CDC measure for communities considering whether to require face coverings in public indoor settings.
The Food and Drug Administration yesterday alerted health care providers and the public to three COVID-19 antigen tests that are not authorized or approved for distribution or use in the United States.
The Centers for Disease Control and Prevention today announced a major adjustment of its federal masking guidance pertaining to the COVID-19 public health emergency, including changes to the metrics that communities are urged to use when determining whether to require face coverings in indoor…
The Food and Drug Administration authorized a revised dosing regimen for the combination monoclonal antibody therapy Evusheld when used to prevent COVID-19 in certain patients, citing data showing a higher initial dose may better prevent infection by certain omicron subvariants.
The Centers for Disease Control and Prevention said some people may wish to receive their second dose of the Pfizer or Moderna COVID-19 vaccine up to eight weeks after the first, especially males aged 12 to 39.
The Centers for Medicare & Medicaid Services has released Medicare payment codes effective Feb. 11 for administering the monoclonal antibody bebtelovimab, effective against the omicron COVID-19 variant.
The Food and Drug Administration announced a Class 1 recall of the E25Bio COVID-19 Direct Antigen Response Test, which was marketed and distributed to U.S. customers without authorization or approval.